Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG

LONDON,July 8, 2026/PRNewswire/ -- Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient formulations provide the essential environment for growing and maintaining cells used in biopharmaceutical manufacturing, vaccine production, regenerative medicine, and advanced biomedical research.

The globalcell culture media marketis growing rapidly, expected to be valued at around US$5.3 billion in 2026 and projected to reach US$12.9 billion by 2033, with a CAGR of 13.6% during the forecast period. This expansion is driven by increasing biologics manufacturing, rapid commercialization of cell and gene therapies, and growing adoption of serum-free and chemically defined production systems. Cell culture media serve as the foundation of modern bioprocessing, supporting the production of monoclonal antibodies, vaccines, recombinant proteins, and regenerative therapies.

The rapid expansion of global biopharmaceutical manufacturing is creating sustained demand for advanced cell culture media. Pharmaceutical companies continue investing in large-scale biologics production facilities to meet rising demand for monoclonal antibodies, biosimilars, vaccines, and recombinant proteins. Cell culture media play a critical role by supplying the nutrients required for high-density mammalian cell cultivation throughout commercial manufacturing processes.

Multiple biologics manufacturing facilities announced capacity expansions to support growing therapeutic pipelines, while regulatory agencies strengthened guidance supporting advanced biologics and cell therapy manufacturing. Manufacturers increasingly prefer chemically defined and serum-free media because they deliver greater batch consistency, reduce contamination risks, and simplify regulatory compliance. These formulations also improve production efficiency by supporting higher cell densities and predictable manufacturing performance.

Beyond commercial biologics,regenerative medicineand personalized therapies continue creating new demand for specialized media formulations. Cell and gene therapy developers require highly optimized nutrient systems capable of supporting complex cell expansion protocols while maintaining product quality. North America remains the largest manufacturing hub, while Asia Pacific continues investing heavily in localized biologics production infrastructure. Overall, expanding biopharmaceutical production ensures long-term growth opportunities for media manufacturers developing high-performance, regulatory-compliant formulations.

• The global cell culture media market is projected to grow from US$5.3 billion in 2026 to US$12.9 billion by 2033, registering a CAGR of 13.6%.

• Serum-free media is expected to lead the product segment with around 38% market share, supported by increasing adoption of animal-origin-free manufacturing.

• Chemically defined media is anticipated to be the fastest-growing product type, driven by demand for greater batch consistency and regulatory compliance.

• Biopharmaceutical production is projected to account for approximately 44% of market share, fueled by expanding biologics and vaccine manufacturing.

• North America is expected to hold around 42% of the market share, while Asia Pacific is forecast to witness the fastest growth through 2033.

The transition toward chemically defined and serum-free media has become one of the strongest growth drivers for the cell culture media market. Regulatory agencies and pharmaceutical manufacturers are steadily moving away from animal-derived ingredients to improve biological safety, eliminate variability, and strengthen manufacturing reproducibility. This shift has accelerated significantly as commercial biologics production expands worldwide.

Chemically defined formulations allow manufacturers to maintain precise control over every media component, resulting in consistent cell growth and improved production yields. Serum-free media minimize contamination risks while simplifying downstream purification and regulatory validation. These advantages have made both formulations increasingly attractive across vaccine manufacturing, monoclonal antibody production, stem cell expansion, and advanced therapeutic development.

Technology innovation is further supporting this transition. Companies are investing in recombinant growth factors, AI-assisted nutrient optimization, and customized media formulations designed for specific cell lines. Automated upstream manufacturing platforms also integrate more effectively with chemically defined media, improving scalability while reducing production costs. As regulatory expectations continue emphasizing manufacturing consistency and traceability, demand for advanced media formulations is expected to accelerate throughout the forecast period.

• A notable development highlighted by Thermo Fisher Scientific is the promotion of Gibco™ BenchStable™ media, a cell culture medium formulated to remain stable at ambient temperatures rather than requiring refrigerated storage. According to the company, the product is designed to help laboratories reduce dependence on cold-chain storage while maintaining the performance expected for routine cell culture applications.

• Thermo Fisher explains that conventional cell culture media typically require refrigerated transportation and storage, contributing to energy consumption and greenhouse gas emissions throughout the product lifecycle. By contrast, Gibco™ BenchStable™ media can be stored at room temperature, reducing refrigeration requirements during storage and laboratory use. The company states that this supports laboratory sustainability initiatives by lowering energy usage and minimizing the environmental impact associated with cold-chain logistics.

The company also notes that ambient storage offers operational benefits for laboratories, including freeing up refrigerator space, simplifying media handling, and improving workflow convenience by eliminating the need to warm media after refrigerated storage. Thermo Fisher positions Gibco™ BenchStable™ media as part of its broader effort to help research laboratories adopt more sustainable practices without changing established cell culture protocols or compromising ease of use.

Serum-free media is expected to account for around 38% of the market share, making it the leading product type as biopharmaceutical manufacturers increasingly transition away from animal-derived components to improve biological safety, batch consistency, and regulatory compliance. The segment continues to benefit from growing commercial biologics production and stricter contamination-control standards. Meanwhile, chemically defined media is projected to register the fastest CAGR through 2033, supported by rising demand for precision bioprocessing, reproducible manufacturing, and automated upstream production systems. Reflecting this trend, Merck KGaA expanded its portfolio of chemically defined cell culture media solutions designed for high-density mammalian cell cultivation, enabling improved scalability and manufacturing efficiency for commercial therapeutic production. These developments reinforce the industry's shift toward highly standardized and regulatory-compliant media formulations.

North America holds the largest share of the cell culture media market, accounting for approximately 42% of global value due to its advanced biopharmaceutical manufacturing infrastructure, extensive biologics pipelines, and significant investments in cell and gene therapy development. The United States leads regional demand through expanding commercial manufacturing facilities, strong research funding, and continuous regulatory support for advanced biologics production. Canada contributes through growing vaccine manufacturing capacity and increasing biotechnology partnerships.

Asia Pacific is the fastest-growing region, projected to record the highest CAGR through 2033. China continues expanding domestic biologics manufacturing capacity through major investments in biosimilars and commercial bioprocessing infrastructure. India strengthens regional growth through increasing pharmaceutical manufacturing capabilities and expanding contract development and manufacturing organizations, while Japan benefits from continued advances in regenerative medicine and induced pluripotent stem cell research.

Europe maintains a significant market position, supported by strong biosimilar manufacturing, rigorous quality standards, and established contract manufacturing organizations. Latin America and the Middle East continue witnessing gradual growth as governments increase investments in biotechnology infrastructure and localized vaccine production. These regional trends encourage manufacturers to strengthen local production capabilities while improving supply chain resilience and reducing delivery timelines.

Leading players include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, Sartorius AG, and Lonza Group.

• Thermo Fisher Scientific continues expanding manufacturing capacity for serum-free and specialty media to support global biologics production.

• Merck KGaA focuses on chemically defined formulations designed for high-density mammalian cell cultivation and automated upstream processing.

• Danaher Corporation strengthens its position through integrated bioprocessing solutions supporting drug discovery, development, and commercial manufacturing.

• Sartorius AG expands advanced cell culture technologies while investing heavily in scalable bioprocessing platforms for cell and gene therapy production.

Across the market, competitive strategies emphasize product innovation, manufacturing expansion, regulatory compliance, customized formulations, and long-term partnerships with biopharmaceutical manufacturers.

• Serum-free Media

• Classical Media

• Stem Cell Culture Media

• Specialty Media

• Chemically Defined Media

• Other Cell Culture Media

• Liquid Media

• Semi-solid and Solid Media

• Biopharmaceutical Production

• Drug Screening and Development

• Tissue Engineering and Regenerative Medicine

• Diagnostics

• Research Applications

• Others

• North America

• Europe

• East Asia

• South Asia & Oceania

• Latin America

• Middle East & Africa

Microcarrier Beads Marketby Product Type (Collagen Coated Beads, Cationic Beads), Material (Natural, Synthetic), Target Cell (CHO, HEK, Vero), Application (Biopharmaceutical Production, Regenerative Medicine), and Regional Analysis, 2026 – 2033

Serum Free Media Marketby Media (Chinese Hamster Ovary (CHO) Cell Culture Media, Protein Expression Media, Stem Cell Media, Hybridoma Media, Primary Cell Media, Insect Cell Media, and Others), Application (Cancer Research, Vaccine Development, Regenerative Medicines, Cell-based Therapies, Stem-cell Research, and Others), End-use, and Regional Analysis from 2025 – 2032

GMP Biologics Marketby Product Type (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Cell & Gene Therapies), Application (Cancer, Infectious Diseases, Autoimmune Diseases, Rare Diseases), End User (Pharmaceutical Companies, Biotechnology Companies, Research Institutes), by Regional Analysis, 2026 - 2033

Cell Tissue Culture Supplies Marketby Product (Media, Sera, Reagents, Vessels, Accessories), Application, End-User, and Regional Analysis for 2025 – 2032

3D Cell Culture Marketby Product (Medical Imaging Equipment, Operating Room & Surgical Equipment, Critical Care Devices, Patient Monitoring Devices, Neurology Devices, Cardiovascular Devices, Endoscopy Devices, and Others), Application (Cardiology, Neurology, Oncology, Orthopedics, Gynecology, and Others), End-user (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers (ASCs), and Specialty Clinics), and Regional Analysis from 2026 – 2033

Recombinant Cell Culture Supplements Marketby Product (Recombinant Growth Factors, Recombinant Insulin, Recombinant Albumin, Recombinant Transferrin, Recombinant Trypsin, Recombinant Aprotinin, Recombinant Lysozyme, Others), by Source (Animals, Microorganisms, Human), by Application, by End User, and Regional Analysis from 2025 – 2032

Mucosal Melanoma Treatment Marketby Treatment Type (Surgery, Chemotherapy, Immunotherapy, Radiation Therapy), Application (Hospitals, Clinics, Research Institutions), and Regional Analysis, 2026 - 2033

Tissue Culture Reagents Marketby Product Type (Media, Growth Factors, Enzymes, Antibiotics, Buffers, Serum), Application Type (Plant Tissue Culture, Animal Cell Culture, Microorganism Culture, Stem Cell Research, Pharmaceutical Development), End-use (Research Laboratories, Biopharmaceutical Companies, Agricultural Companies, Contract Research Organizations (CROs), Academic Institutions), and Regional Analysis for 2025 – 2032

Protein Purification and Isolation Marketby Product Type (Instruments, Consumables), Technology (Ultrafiltration, Precipitation), Application (Drug Screening, Biomarker Discovery), and Regional Analysis, 2026 – 2033

Electroporation Instruments Marketby Product Type (Instruments, Accessories), Application (Protein Production, Therapeutic Delivery, Biomedical Research), End-user (Hospital Laboratories, Research and Academic Institutes, Pharmaceutical Industries), and Regional Analysis for 2026 - 2033

At Persistence Market Research, we are pioneers in Market Research and Consulting, bringing you the most dynamic insights into market trends, consumer behaviours, and competitive intelligence! For over a decade, we've been at the forefront of delivering game-changing analytics and research that drive businesses toward growth.

Our extensive market report database is a go-to resource for Fortune 500 companies, savvy business investors, media and entertainment channels, and academic institutions, empowering them to navigate the global and regional business landscape with confidence. With thousands of statistics and in-depth analyses covering over 20 diverse industries across 25 major countries, we provide the insights you need to succeed in today's competitive environment.

ContactAnkush NikamPersistence Market ResearchSecond Floor, 150 Fleet Street, London, EC4A 2DQ+44 203-837-5656United KingdomUSA Phone - +1 646-878-6329Email:[email protected]